GlobeImmune

GlobeImmune, Inc.
Public
Traded as NASDAQ: GBIM
Industry Biotechnology
Headquarters Louisville, Colorado, United States
Number of employees
 22 (Dec 2014)[1]
Website GlobeImmune.com

GlobeImmune, Inc. is a clinical-stage public biopharmaceutical company headquartered in Louisville, Colorado, that develops therapeutic vaccines to treat cancer and infectious diseases.[2] As of August 2014, the company had no marketed products.[3] GlobeImmune’s therapeutic vaccines are developed on the company’s Tarmogen immunotherapy platform. Tarmogens are made from genetically modified yeast that express one or more disease-associated antigens. Tarmogens activate T cells to specifically target and eliminate diseased cells with the same target antigen.

Tarmogen platform

The company has partnerships with Celgene (established in 2009)[2] and the National Cancer Institute for the development of cancer vaccines,[4][5] and with Gilead for the development of therapeutic vaccines for the treatment of hepatitis B.[6]

With respect to financing in the absence of revenue, the company raised US$17.5 million through a Series E Preferred Stock offering in January 2010.[2]

As of August 2015, GlobeImmune had two therapeutic vaccines in clinical trials, GI-6207 and GI-6301, for the treatment of various cancers.[7] Completed trials have addressed two other candidates, GI-4000 (the company's lead oncology candidate as of 2010)[2] and GI-5005.[7] Despite there being three ongoing trials, in July 2015 the company announced it would eliminate "most of its workforce positions" shortly following the failure of a trial examining GI-4774.[1]

References

  1. 1 2 Staff (July 2015). "GlobeImmune Authorizes Laying Off Most of Its Workforce". Industry Watch. Genetic Engineering & Biotechnology News (paper) 35 (13). p. 8.
  2. 1 2 3 4 Staff (19 January 2010). "GlobeImmune Raises $17.5M in Series E Financing". Genetic Engineering & Biotechnology News. Retrieved 2015-08-19.
  3. ↑ "About GlobeImmune" (PDF). GlobeImmune. 22 August 2014. Retrieved 2015-08-19.
  4. ↑ "GlobeImmune and Celgene Corporation Announce Strategic Global" (Press release). Celgene. 15 May 2009 – via Bloomberg.
  5. ↑ Staff (16 April 2009). "GlobeImmune starts cancer drug trial". BizWest (Colorado, United States: BizWest Media).
  6. ↑ Avery, Greg (24 October 2011). "GlobeImmune, Gilead team up on hepatitis B treatment". Denver Business Journal.
  7. 1 2 "Search of:globeimmune". ClinicalTrials.gov. United States National Institutes of Health.

External links

This article is issued from Wikipedia - version of the Wednesday, October 07, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.